


THE EPA BI-MONTHLY MEETING INORGANIC ARSENIC SCIENCE DISCUSSION

KIMBERLY WISE, PhD ACC CENTER FOR ADVANCING RISK ASSESSMENT SCIENCE AND POLICY JUNE 26 – 27, 2014



SCIENCE ISSUE 2: RISK-OF-BIAS (ROB) APPROACH



Identifying Studies for Use in RoB




Figure 1-4 Overall Process for Identifying Studies for the Toxicological Review

Recommendations

- Literature search should focus on relevant exposure ranges, as suggested by NRC
 - Table 1-9, should not exclude episodic/acute exposure. This can inform potential toxicity and metabolism.
- Fit for purpose evaluation should be conducted before a RoB/ quality evaluation
 - Should incorporate QA/QC into quality criteria.
- RoB/quality evaluation should be conducted for all data streams, including mechanistic data.
 - Criteria for scoring may need to be adjusted based on design limitations of ecological studies
- Apparent Disconnect between Figure 1-4 and process followed in Section 2
 - literature flow diagram treats mechanistic, MOA, PBPK and other important information as "other studies" that are not evaluated on par with animal and human data.

Excerpt from Figure 1-4, Page 1-47

Determining Data Tiers for RoB (Table 1-8)

OHAT Risk of Bias Questions	Risk of bias ratings												
Were the comparison groups appropriate? (Confidence in observed association)	++ or+	Anv		Two of the three questions are –	Three of the other four questions are –		No more than one of the other five questions is a –	++ or +					
Did the study design or analysis account for important confounding and modifying variables? (Confidence in observed association)	++ or+	An An		Two of the three questions are –	-	Three of the other four questions are –	No more than one of the other five questions is –	++ or +					

Tiering data	Low risk of bias	High Risk of Bias	High Risk of Bias	High Risk of Bias	High Risk of Bias	High Risk of Bias	Low risk of bias	Low risk of bias
--------------	---------------------------	----------------------	----------------------------	----------------------	----------------------------	----------------------	------------------	------------------

Concerns/Issues

- ☐ Scoring is not clear as presented in the table
- Explanation on Page 2-14 is unclear
 - Sometimes 6 questions are referred to; other times three or four questions are referred to.
 - If a study did not measure arsenic, why would it have a low risk of bias?
- ☐ How will supporting evidence inform assessments?
 - For this evidence has high RoB and/or low quality scores, why should it be used at all?

RoB Approach for Animal Studies

Concerns/Issues

Table 1-6 Example Risk of Bias Considerations

Category	Risk of Bias Questions*								
Selection	Was administered dose or exposure level adequately randomized?								
	Was allocation to study groups adequately concealed?								
	3. Were the comparison groups appropriate?								
	Did the study design or analysis account for important confounding and modifying variables?								
	5. Did researchers adjust or control for other exposures that are anticipated to bias results?								
Performance	6. Were experimental conditions identical across study groups?								
	7. Did researchers adhere to the study protocol?								
	8. Were the research personnel and human subjects blinded to the study group during the study?								
Attrition	Were outcome data complete without attrition or exclusion from analysis?								
Detection	10. Were the outcome assessors blinded to study group or exposure level?								
	11. Were confounding variables assessed consistently across groups using valid and reliable measures?								
	12. Can we be confident in the exposure characterization?								
	13. Can we be confident in the outcome assessment?								
Selective Reporting Bias	14. Were all measured outcomes reported?								
Other	15. Were there no potential threats to internal validity (e.g., statistical methods were appropriate)?								

^{*}Note, in consultation with OHAT, questions number 7, 9 and 15 were restated from the 2013 draft (NTP, 2013) so that answering "yes" would consistently indicate lower risk of bias, while answering "no" would indicate higher risk of bias.

EPA only using Questions 12 and 13 for tiering studies

- If other questions are not important then how are they used to evaluate/integrate?
- If exposure is uncertain (- probably high risk of bias) why not exclude? EPA only excludes definitely high risk of bias
- If there is probably or definitely high risk of bias for outcome assessment, why not exclude/set aside? What will happen with studies that are set aside for additional review or included as supporting evidence?

Are all included studies treated as equal even though some may have more bias than others?

Will other important quality elements from Klimisch and ToxRTool be incorporated? http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/archivepublications/

- species, sex, strain, exposure route and relevance of each
- appropriate positive and negative controls

RoB Approach - Animal Studies

Need Clarification

- ➤ What is the final RoB rating for each study listed?
- ➤ How with they be used for tiering and integration?

Considered Most Important for Tiering

6.2 Risk of Bias Overview - Immune System and Lymphatic Effects

- High Dose Level
- No Blinded Analysis
- UnusualSpecies

Not
Included
in Data
Tables

Study			Selection		Confounding		Performance			Att.	Detection			SRB	Other	
			Allocation Concealment	Comparison Group	Confounding (Design)	Unintended Exposure	Experimental Conditions	Protocol Deviations	Blinding (During Study)	Missing Outcome Data	Blinding (Outcome	Confounding (Analysis)	Exposure Characterization	Outcome As ses sment	Outcome Reporting	Internal Validity
Das et al. (2012b)	Р	++	+	n/a	+	+	+	+	+	-	+	+	+	+	+	++
	Р	-	-	n/a	+	+	++	+	+	-	+	+	-	+	++	++
Nain and Smits (2012)	Р	+	+	n/a	+	+	+	+	+	-	++	+	+	++	+	++
Ramsey et al. (2013b)	Р	-	-	n/a	+	+	+	+	+	++	++	+	-	+	++	++
Sankar et al. (2013)	Р	+	+	n/a	+	+	+	+	+	++	+	+	-	++	+	++
Stepnik et al. (2009)	Р	-	-	n/a	+	+	++	+	+	++	+	+	-	+	#	++
Tokar et al. (2010b)	Р	+	+	n/a	+	+	+	+	+	++	++	+	-	+	+	++
Waalkes et al. (2003)	Р	+	+	n/a	++	+	++	+	+	++	++	+	+	+	+	++
Waalkes et al. (2006a)	Р	+	+	n/a	**	+	++	+	+	++	++	+	+	++	+	++
Waalkes et al. (2006b)	Р	+	+	n/a	++	+	++	+	+	++	++	+	+	#	+	++
	Stepnik et al. (2009)	Das et al. (2012b) Rozul et al. (2009) Pain and Smits (2012) Ramsey et al. (2013b) Sankar et al. (2013) Posar et al. (2009) Tokar et al. (2010b) Waalkes et al. (2003) Posar et al. (2006a)	Das et al. (2012b) P + Kozul et al. (2009) P - Nain and Smits (2012) P + Ramsey et al. (2013b) P - Sankar et al. (2013b) P + Stepnik et al. (2009) P - Tokar et al. (2010b) P + Waalkes et al. (2003) P + Waalkes et al. (2006a) P +	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)	Das et al. (2012b)